Utama › Mieloma Pelbagai › Indiana › Indianapolis
Kajian klinikal Mieloma Pelbagai di Indianapolis, IN
13 kajian untuk Mieloma Pelbagai sedang mencari peserta di lokasi dalam dan sekitar Indianapolis (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 3
- Franciscan Health, Indianapolis
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Mengambil pesertaFasa 4
- Indiana University, Indianapolis
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Mengambil pesertaFasa 2
- Community Health Network (The University of Texas MD Anderson Cancer Center), Indianapolis
Collection of Tissue Samples for Cancer Research
Mengambil pesertaKajian pemerhatian
- Indiana University - Purdue, Indianapolis
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Mengambil pesertaFasa 3
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Mengambil pesertaFasa 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- IU Health Methodist Hospital, Indianapolis
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Mengambil pesertaFasa 1
- Indiana University, Indianapolis
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Mengambil pesertaFasa 2
- Indiana University Health, Indianapolis
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 1
- Franciscan St. Francis Health /ID# 280928, Indianapolis
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Mengambil pesertaFasa 1
- Indiana University Health Simon Cancer Center, Indianapolis
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Mengambil pesertaFasa 1/2
- Community Health Network, Indianapolis
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Mengambil pesertaFasa 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Saint Catherine Hospital, Indianapolis
The Indiana Myeloma Registry
Mengambil pesertaKajian pemerhatian
- Indiana University Simon Cancer Center, Indianapolis
Kajian Mieloma Pelbagai di bandar lain
- New York City, NY60 kajian
- Boston, MA42 kajian
- Atlanta, GA41 kajian
- Houston, TX38 kajian
- Durham, NC37 kajian
- Nashville, TN32 kajian
- Denver, CO27 kajian
- Rochester, MN24 kajian
- St. Louis, MO24 kajian
- Columbus, OH24 kajian
- Baldwin Park, CA23 kajian
- Chicago, IL22 kajian
Kajian lain di Indianapolis
- Kanser Paru-paru Bukan Sel Kecil32 kajian
- Kanser (semua jenis)24 kajian
- Kegagalan Jantung23 kajian
- Kanser Payudara20 kajian
- Obesiti20 kajian
- Kanser Metastatik19 kajian
- Kanser Kolorektal18 kajian
- Kanser Ovari17 kajian
- Kanser Paru-paru16 kajian
- Penyakit Kardiovaskular16 kajian
- Diabetes Jenis 114 kajian
- Kanser Endometrium14 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.